ROBERT A. O'REILLY, M.D., F.A.C.P.
Supported in part by grant HE 8058-09, U.S. Public Health Service, Washington, D.C.
▸Requests for reprints should be addressed to Robert A. O'Reilly, M.D., Santa Clara Valley Medical Center, 751 S. Bascom Ave., San Jose, Calif. 95128.
O'REILLY R.; Interaction of Sodium Warfarin and Disulfiram (Antabuse®) in Man. Ann Intern Med. 1973;78:73-76. doi: 10.7326/0003-4819-78-1-73
Download citation file:
Published: Ann Intern Med. 1973;78(1):73-76.
To evaluate the interaction of sodium warfarin and disulfiram (Antabuse®), a single dose (1.5 mg/kg body weight) and a 21-day course of sodium warfarin were administered orally, with and without disulfiram orally, to eight normal subjects. A significant augmentation of both the hypoprothrombinemia (P < 0.01) and the plasma warfarin level (P < 0.05) occurred with daily disulfiram compared with warfarin alone, for both the single-dose and 21-day experiments. In the single-dose and 21-day experiments a highly significant correlation of the changes in plasma warfarin levels and in the hypoprothrombinemia occurred, which was positive in 13 and negative in 2 experiments. We conclude that disulfiram increases the anticoagulant effect of warfarin therapy in most but not all subjects by inhibiting its metabolism in the liver. An augmentation of the therapeutic effect of a drug by disulfiram has thus been shown for the first time in humans.
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Gastroenterology/Hepatology, Hematology/Oncology, Coagulopathies, Liver Disease.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only